10-K: Humana's 2025 Performance: MA Decline, CenterWell Growth Amid Regulatory Challenges

Humana reports mixed 2025 results with a decline in individual Medicare Advantage members and lower net income, offset by strong growth in CenterWell services and state-based contracts, while navigating significant regulatory and legal headwinds.

Summary

• Net income attributable to Humana was $1.2 billion in 2025, a slight decrease from $1.2 billion in 2024.
• Diluted earnings per common share decreased to $9.84 in 2025 from $9.98 in 2024.
• Consolidated premiums revenue increased by 9.6% to $122.8 billion in 2025, primarily due to higher per member Medicare premiums (driven by the IRA) and growth in state-based contracts and stand-alone PDP businesses.
• Consolidated services revenue grew by 31.6% to $5.8 billion in 2025, mainly from external growth in primary care and pharmacy solutions.
• The consolidated benefit ratio increased by 40 basis points to 90.2% in 2025, influenced by business mix shifts and the IRA's impact on Medicare stand-alone PDP.
• Individual Medicare Advantage membership decreased by 7.3% to 5.2 million members in 2025, partly due to exiting unprofitable plans and counties.
• Medicare stand-alone PDP membership increased by 7.6% to 2.46 million members in 2025.
• State-based contracts membership increased by 10.7% to 1.6 million members in 2025.
• CenterWell segment's external services revenue increased by 39.0% to $4.8 billion in 2025.
• The company incurred $449 million in charges for value creation initiatives in 2025, including $329 million in severance and employee-related charges.
• Impairment charges totaled $253 million in 2025, including $128 million for indefinite-lived intangible assets.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative report. While there are areas of growth in CenterWell and state-based contracts, the decline in individual Medicare Advantage membership, lower net income, and significant regulatory/legal challenges, particularly concerning Star Ratings and RADV audits, present considerable headwinds and uncertainty.

Positives

• Consolidated services revenue increased significantly by 31.6% to $5.8 billion in 2025, driven by external growth in primary care and pharmacy solutions businesses.
• State-based contracts and Medicare stand-alone PDP businesses experienced strong membership growth, increasing by 10.7% and 7.6% respectively in 2025.
• The company achieved administrative cost efficiencies from value creation initiatives, partially offsetting other operating cost increases.
• Favorable prior-period medical claims reserve development of $1.0 billion in 2025, an increase from $701 million in 2024, indicating consistent actuarial estimates.
• All material contracts with CMS for Medicare products have been renewed for 2026, and all product offerings for 2026 have been approved.
• The company maintains a strong liquidity position with cash and cash equivalents increasing to $4.2 billion at December 31, 2025, from $2.2 billion at December 31, 2024.

Negatives

• Net income attributable to Humana slightly decreased from $1.214 billion in 2024 to $1.203 billion in 2025.
• Diluted earnings per common share decreased from $9.98 in 2024 to $9.84 in 2025.
• Individual Medicare Advantage membership declined by 7.3% (412,500 members) in 2025, partly due to exiting unprofitable plans and counties.
• The consolidated benefit ratio increased by 40 basis points to 90.2% in 2025, influenced by a shift to lines of business with higher benefit ratios and the IRA's impact on Medicare stand-alone PDP.
• Investment income decreased by 17.9% to $1.0 billion in 2025, primarily due to lower interest income on debt securities and a non-cash impairment charge.
• Operating costs increased by 12.8% to $15.5 billion in 2025, driven by business mix changes (CenterWell's higher operating cost ratio), operating leverage impact from MA membership loss, and higher charges for value creation initiatives.
• The number of Medicare Advantage plans rated 4-star or higher significantly declined in 2025, which will negatively impact 2026 quality bonus payments from CMS.
• The company recorded $449 million in charges for value creation initiatives and $253 million in impairment charges in 2025, impacting profitability.

Risks

• Inability to design and price products competitively, or if premiums are insufficient to cover healthcare costs, could materially adversely affect profitability.
• Highly competitive industry with barriers to entry not substantial, leading to potential loss of market share and pressure on premium prices.
• Governmental policies and decisions regarding Medicare Advantage, Prescription Drug Plans, military services, and Medicaid programs substantially impact profitability, with potential for reduced premium payments or increased costs.
• Failure to effectively implement operational and strategic initiatives, including Medicare initiatives and growth of CenterWell businesses, could materially adversely affect the business.
• The significant decline in 2025 Medicare Advantage Star Ratings will negatively impact 2026 quality bonus payments and may adversely affect revenues, operating results, and cash flows.
• Uncertainties with ongoing changes to the Star Ratings system and CMS cut-points make accurate prediction of future Star Ratings challenging.
• Failure to properly maintain data integrity, implement new information systems (including AI/ML), or protect proprietary rights could lead to operational disruptions, reputational damage, and regulatory obstacles.
• Inability to defend information technology systems against cybersecurity attacks or prevent data security incidents could result in significant regulatory fines, liability, or reputational damage.
• Involvement in various legal actions and governmental investigations, including qui tam lawsuits related to Medicare risk adjustment practices and the RADV Rule lawsuit, could result in substantial monetary damages or changes in business practices.
• As a government contractor, exposure to risks from federal and state health care coverage programs, including potential reductions in Medicare reimbursement rates or changes in program rules.
• The Final RADV Rule, eliminating the Fee-for-Service Adjuster and expanding audit efforts, could have a material adverse effect on results of operations, financial position, or cash flows.
• New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or their application, could increase the cost of doing business.
• Potential enforcement actions by governmental officials alleging non-compliance with corporate practice of medicine, fee-splitting, and similar state laws.
• Risks associated with managing acquisitions, divestitures, and other significant transactions, including integration challenges and failure to meet strategic objectives.
• Failure to develop and maintain satisfactory relationships with providers, including managing costs under capitation arrangements, could adversely affect the business.
• Significant competition in attracting and retaining talented employees and executives, with potential adverse effects on business and performance if not managed effectively.
• The pharmacy solutions business is highly competitive and subjects the company to additional regulations and distribution/supply chain risks.
• Changes in prescription drug industry pricing benchmarks (e.g., AWP to ASP) may adversely affect financial performance.
• Restrictions by state insurance regulations on obtaining funds from licensed subsidiaries could impact the parent company's ability to fund obligations.
• Downgrades in debt ratings could adversely affect the business, increasing borrowing costs and potentially decreasing sales and earnings.
• Volatility or disruption in securities and credit markets, including interest rate changes, may significantly and adversely affect the value of the investment portfolio and investment income.

Future Outlook

The company anticipates net membership growth in individual Medicare Advantage offerings of approximately 25% for the full year 2026. Net membership growth in group Medicare Advantage offerings is expected to be approximately 150,000 members, and Medicare stand-alone PDP offerings are projected to grow by approximately 1,000,000 members for the full year 2026. State-based contracts are expected to see net membership growth in a range of 25,000 to 100,000 members for 2026. The company expects to incur additional charges over the course of its multi-year transformation program.

Management Comments

• Committed to putting health first – for teammates, customers, and the company.
• Making it easier for the millions of people served to achieve their best health – delivering the care and service they need, when they need it.
• These efforts are leading to a better quality of life for Medicare and Medicaid participants, families, individuals, military service personnel, and communities at large.
• Our strategy is to offer members affordable health care combined with a positive consumer experience in growing markets.
• The integrated care delivery model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering members a simple, seamless healthcare experience.
• We believe this strategy is positioning us for long-term growth in both membership and earnings.
• We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members.
• It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act.

Industry Context

StockSavvy.ai notes that Humana's performance reflects broader industry trends, including the increasing importance of government-sponsored health programs like Medicare Advantage and Medicaid, which constitute a significant portion of its revenue. The impact of the Inflation Reduction Act of 2022 (IRA) on Medicare Part D benefit design and direct subsidies is a key factor shaping revenue and benefit ratios across the sector. The decline in Medicare Advantage Star Ratings is a sector-wide concern, impacting quality bonus payments and competitive positioning. The company's strategic focus on integrated care delivery through its CenterWell segment aligns with the industry's shift towards value-based care models and population health management, aiming to improve outcomes and control costs. The competitive landscape remains intense, with pricing pressure and the need for continuous innovation in product offerings and provider networks.

Comparison to Industry Standards

• The decline in Medicare Advantage Star Ratings for 2025 places Humana at a disadvantage compared to competitors who maintain higher ratings, as this directly impacts quality bonus payments and market attractiveness.
• The increase in the consolidated benefit ratio to 90.2% in 2025, while influenced by business mix, suggests a higher medical loss ratio compared to some industry peers who may have more favorable member risk profiles or more effective cost management strategies.
• The growth in the CenterWell segment's external services revenue by 39.0% indicates strong performance in value-based care and integrated services, potentially outpacing some traditional health plan competitors still heavily reliant on fee-for-service models.
• The 7.3% decline in individual Medicare Advantage membership contrasts with the overall growth trend in the MA market, suggesting competitive pressures or strategic exits from less profitable areas, which may be a deliberate choice but impacts market share relative to peers like UnitedHealth Group or CVS Health (Aetna).
• The company's investment in value creation initiatives and a multi-year transformation program to realign cost structure and technology footprint is a common response across the healthcare industry to evolving market conditions and regulatory pressures, similar to efforts seen at other large payers to enhance efficiency and adapt to new payment models.

Management Changes

Corporate Governance

Legal Proceedings

• Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services regarding the Final RADV Rule. The Court granted summary judgment to Humana and vacated the rule on September 25, 2025, but the government appealed on November 21, 2025.
• A putative stockholder class action, 'In re Humana Inc. Securities Litigation,' was filed in June 2024, alleging false or misleading statements about financial performance, medical costs, Star Ratings, and distribution relationships in Medicare Advantage.
• Parallel stockholder derivative actions, 'In re Humana Shareholder Derivative Action' and 'Nicolaou v. Broussard,' were filed between July 2024 and March 2025, alleging breach of fiduciary duty by current and former directors and executive officers related to the same claimed acts and omissions.
• Humana Inc. and Americans for Beneficiary Choice filed suit against HHS regarding the Medicare Advantage and Part D Star Ratings program. The Court rejected Humana's challenge to the 2025 Star Ratings on October 14, 2025, and Humana appealed on November 25, 2025.
• On May 1, 2025, the Department of Justice filed a complaint in partial intervention related to a qui tam lawsuit ('United States of America ex. rel. Andrew Shea v. eHealth, Inc., et al.') alleging civil violations concerning non-commission payments to broker partners and marketing of Medicare Advantage plans.
• On December 30, 2025, the United States Court of Appeals for the Sixth Circuit denied Humana's petition to appeal a district court order certifying a class in 'David Elliott v Humana Inc.,' alleging violations of the Telephone Consumer Protection Act (TCPA).

Related Party Transactions

• The primary care business previously entered into a strategic partnership with Welsh, Carson, Anderson & Stowe (WCAS) to expand primary care clinics. As of December 31, 2025, there were 146 clinics under this partnership. Agreements include put and call options through which WCAS may require Humana to purchase their interest, or Humana may acquire WCAS's interest, over the next 1 to 9 years, with potential purchases of $1.0 billion to $1.5 billion for the first two cohorts in 2026 and $3.0 billion to $5.0 billion for all existing cohorts through 2034.
• The company owns certain corporate debt securities of Gentiva Hospice, with book value and fair value of $381 million and $383 million, respectively, at December 31, 2025. Humana also holds a 35% minority ownership interest in Gentiva Hospice, accounted for using the equity method.

Stakeholder Impact

• Shareholders: Impacted by decreased net income and EPS, ongoing legal and regulatory uncertainties, and the significant decline in Medicare Advantage Star Ratings which affects future quality bonus payments. Share repurchase programs and dividends aim to return value.
• Customers (Members): Affected by changes in Medicare Advantage plan offerings (exiting unprofitable counties), potential changes in benefits due to regulatory shifts (IRA impact on Part D), and the company's integrated care delivery model aiming for improved health outcomes and affordability.
• Employees (Associates): Impacted by workforce optimization and severance charges as part of value creation initiatives. The company emphasizes recruiting, developing, and retaining diverse teams, with a focus on culture, engagement, and competitive pay/benefits.
• Providers: Relationships are critical, with a focus on transitioning to value-based arrangements. Legal proceedings related to risk adjustment and claims practices could affect provider interactions and compensation.
• Regulatory Authorities: Actively engaged in legal disputes with CMS and the Department of Justice regarding RADV audits, Star Ratings, and other compliance matters, indicating heightened scrutiny.

Next Steps

• Continue to implement clinical initiatives to improve member experience, lower healthcare costs, and appropriately document member risk profiles.
• Focus on achieving anticipated net membership growth in individual Medicare Advantage (25%), group Medicare Advantage (150,000 members), Medicare stand-alone PDP (1,000,000 members), and state-based contracts (25,000-100,000 members) for 2026.
• Vigorously defend against allegations in the ongoing lawsuits, including the RADV Rule lawsuit, the stockholder class action, and the eHealth qui tam action.
• Monitor and adapt to changes in the Medicare Advantage and Prescription Drug Plans, military services, and Medicaid programs, including the implementation of the Inflation Reduction Act.
• Continue the multi-year transformation program to re-align cost structure, operating model, and technology footprint.
• Integrate the primary care business acquired on February 13, 2026.
• Manage the put and call options related to the strategic partnership with Welsh, Carson, Anderson & Stowe for primary care clinics, with potential purchases of $1.0 billion to $1.5 billion in 2026 and $3.0 billion to $5.0 billion through 2034.

Key Dates

Recommendation

The company faces significant headwinds, including a decline in individual Medicare Advantage membership, increased benefit ratio, and ongoing legal and regulatory challenges related to Star Ratings and RADV audits, which create substantial uncertainty. While the CenterWell segment shows strong growth and the company is undertaking value creation initiatives, these positives are currently offset by the pressures on its core insurance business and the potential for adverse outcomes from litigation. A 'hold' recommendation is appropriate given the mixed performance and the need for clarity on the resolution of key regulatory and legal issues before a more definitive stance can be taken.

Keywords

Medicare Advantage, Health Insurance, CenterWell, Pharmacy Solutions, Primary Care, Home Solutions, SEC Filing, 10-K, Healthcare Services, Risk Adjustment, Star Ratings, Medicaid, Prescription Drug Plans, Financial Performance, Regulatory Compliance, Cybersecurity, Legal Proceedings, Debt, Share Repurchase